Sodium colistimethate loaded lipid nanocarriers for the treatment of Pseudomonas aeruginosa infections associated with cystic fibrosis

International Journal of Pharmaceutics

Volumn 477, Issue 1-2, 2014, Pages 485-494

  Pastor, Marta ^a,b   Moreno Sastre, María ^a,b   Esquisabel, Amaia ^a,b   Sans, Eulàlia ^c   Viñas, Miguel ^c   Bachiller, Daniel ^d,e   Asensio, Víctor José ^d   Del Pozo, Ángel ^d   Gainza, Eusebio ^d   Pedraz, José Luis ^a,b  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Fundación Investigaciones Sanitarias Islas Baleares ^*  (Spain)

^e CSIC   (Spain)

Author keywords

Cystic fibrosis; Lipid nanoparticles; Nanomedicine; NLC; Pseudomonas aeruginosa; Sodium colistimethate

Indexed keywords

COLISTIMETHATE; GLYCEROL PALMITOSTEARATE; MANNITOL; MIGLYOL; NANOCARRIER; SOLID LIPID NANOPARTICLE; TREHALOSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ANTIMICROBIAL THERAPY; ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; HUMAN; HUMAN CELL; MALE; MEDICAL NEBULIZER; MOUSE; NONHUMAN; PARTICLE SIZE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; SUSTAINED DRUG RELEASE;

EID: 84910068151     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.10.048     Document Type: Article

References (38)

1. Alvarez, C.A., Wiederhold, N.P., McConville, J.T., Peters, J.I., Najvar, L.K., Graybill, J.R., Coalson, J.J., Talbert, R.L., Burgess, D.S., Bocanegra, R., Johnston, K.P., Williams III, F., 2007. Aerosolized nanostructured itraconazole as prophylaxis against invasive pulmonary aspergillosis. J. Infect. 55, 68-74.
2. Andrade, Rafael, D., Videira, M., Ferreira, D., Sosnik, A., Sarmento, B., 2013. Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases. Adv. Drug Deliv. Rev. 65, 1816-1827.
3. Beloqui, A., Solinís, M.Á., Gascón, A.R., del Pozo-Rodríguez, A., des Rieux, A., Préat, V., 2013. Mechanism of transport of saquinavir-loaded nanostructured lipid carriers across the intestinal barrier. J. Control. Release 166, 115-123.
4. Cancho Grande, B., García Falcón, M., Pérez-Lamela, C., Rodríguez Comesaña, M., Simal Gándara, J., 2000. Quantitative analysis of colistin and tiamulin in liguid and solid medicated premixes by HPLC with diode-array detection. Chromatographia 53, S460-S463.
5. Chono, S., Tanino, T., Seki, T., Morimoto, K., 2008. Efficient drug targeting to rat alveolar macrophages by pulmonary administration of ciprofloxacin incorporated into mannosylated liposomes for treatment of respiratory intracellular parasitic infections. J. Control. Release 127, 50-58.
6. Committee for Medicinal Products for Human Use, CHMP, 2011. European Medicines Agency. Guideline on Bioanalytical Method Validation. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2011/08/WC500109686.pdf, (accessed 04.11.14.).
7. Doktorovova, S., Souto, E.B., Silva, A.M., 2014. Nanotoxicology applied to solid lipid nanoparticles and nanostructured lipid carriers - a systematic review of in vitro data. Eur. J. Pharm. Biopharm. 87, 1-18.
8. Fuste, E., Lopez-Jimenez, L., Segura, C., Gainza, E., Vinuesa, T., Viñas, M., 2013. Carbapenem-resistance mechanisms of multidrug-resistant Pseudomonas aeruginosa. J. Med. Microbiol. 62, 1317-1325.
9. Ghaffari, S., Varshosaz, J., Saadat, A., Atyabi, F., 2011. Stability and antimicrobial effect of amikacin loaded SLN. Int. J. Nanomed. 6, 35-43.
10. Gibson, R.L., Burns, J.L., Ramsey, B.W., 2003. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168, 918-951.
11. Gilani, K., Moazeni, E., Ramezanli, T., Amini, M., Fazeli, M.R., Jamalifar, H., 2011. Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulization. J. Pharm. Sci. 100, 252-259.
12. Gould, I., Bal, A., 2013. New antibiotic agents in the pipeline and how they can help overcome microbial resistance. Virulence 4, 185-191.
13. Heijerman, H., Westerman, E., Conway, S., Touw, D., 2009. Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: a European consensus. J. Cyst. Fibros. 8, 295-315.
14. Koch, C., 2002. Early infection and progression of cystic fibrosis lung disease. Pediatr. Pulmonol. 34, 232-236.
15. Martins, S., Tho, I., Reimold, I., Fricker, G., Souto, E., Ferreira, D., Brandl, M., 2012. Brain delivery of camptothecin by means of solid lipid nanoparticles: formulation design, in vitro and in vivo studies. Int. J. Pharm. 439, 49-62.
16. Nassimi, M., Schleh, C., Lauenstein, H.D., Hussein, R., Hoymann, H.G., Koch, W., Pohlmann, G., Krug, N., Sewald, K., Rittinghausen, S., Braun, A., Müller-Goymann, C., 2010. A toxicological evaluation of inhaled solid lipid nanoparticles used as a potential drug delivery system for the lung. Eur. J. Pharm. Biopharm. 75, 107-116.
17. Obeidat, W.M., Schwabe, K., Müller, R.H., Keck, C.M., 2010. Preservation of nanostructured lipid carriers (NLC). Eur. J. Pharm. Biopharm. 76, 56-67.
18. Omri, A., Suntres, Z.E., Shek, P.N., 2002. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem. Pharmacol. 64, 1407-1413.
19. Patlolla, R.R., Chougule, M., Patel, A.R., Jackson, T., Tata, P.N.V., Singh, M., 2010. Formulation: characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers. J. Control. Release 144, 233-241.
20. Proesmans, M., Vermeulen, F., Boulanger, L., Verhaegen, J., De Boeck, K., 2013. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J. Cyst. Fibros. 12, 29-34.
21. Ratjen, F., Brockhaus, F., Angyalosi, G., 2009. Aminoglycoside therapy against Pseudomonas aeruginosa in cystic fibrosis: a review. J. Cyst. Fibros. 8, 361-369.
22. Ruiz, L., Domínguez, M.A., Ruiz, N., Viñas, M., 2004. Relationship between clinical and environmental isolates of Pseudomonas aeruginosa in a hospital setting. Arch. Med. Res. 35, 251-257.
23. Ruiz-Martinez, L., Lopez-Jimenez, L., d'Ostun, V., Fusté, E., Vinuesa, T., Viñas, M., 2011a. A mechanism of carbapenem resistance due to a new insertion element (ISPa133) in Pseudomonas aeruginosa. Int. Microbiol. 14, 51-58.
24. Ruiz-Martinez, L., Lopez-Jimenez, L., Fuste, E., Vinuesa, T., Martinez, J.P., Viñas, M., 2011b. Class 1 integrons in environmental and clinical isolates of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 38, 398-402.
25. Silva, A.C., Kumar, A., Wild, W., Ferreira, D., Santos, D., Forbes, B., 2012. Long-term stability: biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. Int. J. Pharm. 436, 798-805.
26. Sims, E.J., McCormick, J., Mehta, G., Mehta, A., 2005. Neonatal screening for cystic fibrosis is bene ficial even in the context of modern treatment. J. Pediatr. 147, S42-S46.
27. Soares, S., Fonte, P., Costa, A., Andrade, J., Seabra, V., Ferreira, D., Reis, S., Sarmento, B., 2013. Effect of freeze-drying cryoprotectants and storage conditions on the stability of secondary structure of insulin-AT solid lipid nanoparticles. Int. J. Pharm. 456, 370-381.
28. Souza, A.L.R.D., Andreani, T., de Oliveira, R.N., Kiill, C.P., Santos d, F.K., Allegretti, S.M., Chaud, M.V., Souto, E.B., Silva, A.M., Gremião, M.P.D., 2014. In vitro evaluation of permeation, toxicity and effect of praziquantel-loaded solid lipid nanoparticles against Schistosoma mansoni as a strategy to improve efficacy of the schistosomiasis treatment. Int. J. Pharm. 463, 31-37.
29. Sukhadeve, K., Apte, M., Waghmare, P., 2012. Colistin for bad bugs. Pediatr. Infect. Dis. 4, 168-171.
30. Taratula, O., Kuzmov, A., Shah, M., Garbuzenko, O.B., Minko, T., 2013. Nanostructured lipid carriers as multifunctional nanomedicine platform for pulmonary codelivery of anticancer drugs and siRNA. J. Control. Release 171, 349-357.
31. Ungaro, F., d'Angelo, I., Coletta, C., d'Emmanuele di Villa Bianca, R., Sorrentino, R., Perfetto, B., Tufano, M.A., Miro, A., La Rotonda, M.I., Quaglia, F., 2012. Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: modulation of encapsulation efficiency release rate and lung deposition pattern by hydrophilic polymers. J. Control. Release 157, 149-159.
32. Wang, X.F., Zhang, S.L., Zhu, L.Y., Xie, S.Y., Dong, Z., Wang, Y., Zhou, W.Z., 2012. Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivo. Vet. J. 191, 115-120.
33. Weber, S., Zimmer, A., Pardeike, J., 2014. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) for pulmonary application: a review of the state of the art. Eur. J. Pharm. Biopharm. 86, 7-22.
34. WHO, 2002. The Molecular Genetic Epidemiology of Cystic Fibrosis. Report of a Joint Meeting of WHO/ECFTN/ICF(M)A/ECFS, 1-26.
35. Wong, J.P., Yang, H., Blasetti, K.L., Schnell, G., Conley, J., Schofield, L.N., 2003. Liposome delivery of ciprofloxacin against intracellular Francisella tularensis infection. J. Control. Release 92, 265-273.
36. Worlitzsch, D., Tarran, R., Ulrich, M., Schwab, U., Cekici, A., Meyer, K.C., Birrer, P., Bellon, G., Berger, J., Weiss, T., Botzenhart, K., Yankaskas, J.R., Randell, S., Boucher, R.C., Döring, G., 2002. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 109, 317-325 10.1172/JCI13870.
37. Yue, C., Liu, P., Zheng, M., Zhao, P., Wang, Y., Ma, Y., Cai, L., 2013. IR-780 dye loaded tumor targeting theranostic nanoparticles for NIR imaging and photothermal therapy. Biomaterials 34, 6853-6861.
38. Zheng, M., Falkeborg, M., Zheng, Y., Yang, T., Xu, X., 2013. Formulation and characterization of nanostructured lipid carriers containing a mixed lipids core. Colloids Surf. Physicochem. Eng. Aspects 430, 76-84.